Delpharm acquires an injectable drug development centre

Published on

Delpharm expands its pharmaceutical development services with the acquisition of an injectable drug development centre in the Netherlands

World-leading CDMO Delpharm expands its pharmaceutical development services with the acquisition of the Leiden Development Centre from Dr Reddy’s in the Netherlands. This centre employs forty highly qualified personnel and is located in a 3,500 square meter unit created in 1995, fully equipped with state-of-the-art technologies to develop injectable formulation for small and large molecules and to manufacture small batches for clinical trials.

"We are proud to acquire this centre in Leiden which complements our development services’ offer, organised by technology platforms, for Injectable, Ophthalmic, Oral solid dose, Liquid and Semi solid drugs. We are also making significant investments in our injectable manufacturing facilities throughout the world to offer a one stop shop service to our clients, speeding up the access of new medicines for the patients," said Jean-Bernard Dumas, Chief Scientific Officer.

With the acquisition of the Leiden site, Delpharm is now positioned as a complete player in injectable, from formulation, analytical development, phase 1 clinical batches manufacturing, through regulatory affairs, to production in one of the group’s four injectable plants (3 in France and 1 in Canada).

Delpharm offers the solutions required for the development and production of injectable drugs in all major sterile dosage forms (aseptic filling and /or terminal sterilisation): prefilled syringes, freeze drying, ampoules and vials. Delpharm also has the required expertise to develop and manufacture complex formulations such as liposome, suspension, microsphere, sustained release and emulsion.

Delpharm is delighted to welcome the Leiden team on board and looks forward to working with them to provide our customers with scientific and distinctive services that comply with all major pharmaceutical regulations (EMA, FDA…) and that are based on years of experience on suspensions, microspheres, small and large molecules.